Edesa Biotech FCF yield

Mi az Edesa Biotech FCF yield?

A FCF yield az Edesa Biotech, Inc. - -30.92%

Mi a FCF yield meghatározása?



Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.

ttm (trailing twelve months)

Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.

Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:

Free cash flow yield = Free cash flow per share / market price per share

FCF yield a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest

Mit csinál Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

fcf yield -hoz hasonló cégek Edesa Biotech